The healthcare group Provalis placed itself into voluntary liquidation yesterday after suffering problems with its new diabetes testing kit and running out of cash. It offering investors 0.4p a share ...

DEESIDE healthcare company Provalis has signed an exclusive deal to distribute a respiratory treatment drug in the UK and Ireland. DEESIDE healthcare company Provalis has signed an exclusive deal to ...

Struggling diagnostics company Provalis is selling its remaining business in diabetes testing and will put itself into liquidation. Its shares tumbled from 0.75p to 0.32p after the company said it had ...

Sarbanes-Oxley is forcing pharma company Provalis to delist from Nasdaq just as its US business starts to take off. As Husnara Begum finds, the move is keeping its sole lawyer busy Medical diagnostics ...

DEESIDE- based medical diagnostics and pharmaceuticals group Provalis has made the final payment to Pfizer for its osteo-arthritis treatment Diclomax. DEESIDE- based medical diagnostics and ...

BIOTECH group Provalis increased its hold on the market for the treatment of osteo and rheumatoid arthritis by doing a deal with Parke-Davis, a subsidiary of Pfizer, to take over its Diclomax products ...

HEALTHCARE company Provalis has been awarded £1.6m after arbitration over a disputed contract decided in its favour. HEALTHCARE company Provalis has been awarded #1.6m after arbitration over a ...

Medical diagnostics firm Provalis last night said a strong performance from its diabetes testing product had helped drive annual sales up by almost 50 per cent. The company, based in Deeside, ...

Provalis Research announced the release of an upgraded version of the qualitative analysis freeware QDA Miner Lite, developed to include some of the new features added to the full version of QDA Miner ...

SHAREHOLDERS in Deeside-based healthcare company Provalis have approved the £10.5m sale of its pharmaceutical arm in a move that will give the company cash to enhance a medical diagnostic product.

PROVALIS, the UK biotechnology group, will announce today that its Glycosal diabetes test has been granted two important clearances by the US pharmaceuticals regulator, the Food & Drug Administration.